{"success":true,"data":{"pressRelease":{"id":"17590","rtpr_id":"nGNX6Jq8yc","ticker":"DNTH","exchange":"NASDAQ","all_tickers":["DNTH"],"title":"Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-05-01T20:30:01.933Z","article_body":"NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus\nTherapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company\ndedicated to developing next-generation therapies to transform the treatment\nof severe autoimmune diseases, today announced that it granted equity awards\non May 1, 2026, to six newly-hired, non-executive employees. The inducement\ngrants were approved by the Company's independent Compensation Committee and\nwere made as material inducements to acceptance of employment with Dianthus in\naccordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe inducement grants consist of non-qualified stock options to purchase an\naggregate of 135,000 shares of the Company's common stock with a 10-year term\nand an exercise price of $87.42 per share. The options vest as to 25% on the\nfirst anniversary of the vesting commencement date and in equal monthly\ninstallments for the following 36 months. The inducement grants are subject to\nthe terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement\nPlan, and the terms and conditions of a stock option agreement.\n\nAbout Dianthus Therapeutics\nDianthus Therapeutics, Inc. is a clinical-stage biotechnology company\ndedicated to developing next-generation therapies to transform the treatment\nof severe autoimmune diseases. Based in New York City and Waltham, Mass.,\nDianthus is comprised of an experienced team of biotech and pharma executives\nwho aim to deliver transformative medicines for people living with severe\nautoimmune and inflammatory diseases.\n\nTo learn more, please visit www.dianthustx.com and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ith3p900JWWaR3HeLP5c7eAwkZ9u_GBA824hMEds8-HapXdFeAMGKZpOkFq25cwl7ckOH41cZHlYgHLoAHBBzw1bMJOb0BtZXXwuLTxjTSxHd404JpOTdKCBnw5DAaZRBK5G4pAALPRGfM_RNsKm0g==).\n\nContact \nJennifer Davis Ruff\nDianthus Therapeutics\njdavisruff@dianthustx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c9002285-2240-4dab-aced-77296f86a3fa)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6Jq8yc","title":"Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"DNTH","created":"2026-05-01T20:30:01.933Z","tickers":["DNTH"],"exchange":"NASDAQ","article_body":"NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus\nTherapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company\ndedicated to developing next-generation therapies to transform the treatment\nof severe autoimmune diseases, today announced that it granted equity awards\non May 1, 2026, to six newly-hired, non-executive employees. The inducement\ngrants were approved by the Company's independent Compensation Committee and\nwere made as material inducements to acceptance of employment with Dianthus in\naccordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe inducement grants consist of non-qualified stock options to purchase an\naggregate of 135,000 shares of the Company's common stock with a 10-year term\nand an exercise price of $87.42 per share. The options vest as to 25% on the\nfirst anniversary of the vesting commencement date and in equal monthly\ninstallments for the following 36 months. The inducement grants are subject to\nthe terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement\nPlan, and the terms and conditions of a stock option agreement.\n\nAbout Dianthus Therapeutics\nDianthus Therapeutics, Inc. is a clinical-stage biotechnology company\ndedicated to developing next-generation therapies to transform the treatment\nof severe autoimmune diseases. Based in New York City and Waltham, Mass.,\nDianthus is comprised of an experienced team of biotech and pharma executives\nwho aim to deliver transformative medicines for people living with severe\nautoimmune and inflammatory diseases.\n\nTo learn more, please visit www.dianthustx.com and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ith3p900JWWaR3HeLP5c7eAwkZ9u_GBA824hMEds8-HapXdFeAMGKZpOkFq25cwl7ckOH41cZHlYgHLoAHBBzw1bMJOb0BtZXXwuLTxjTSxHd404JpOTdKCBnw5DAaZRBK5G4pAALPRGfM_RNsKm0g==).\n\nContact \nJennifer Davis Ruff\nDianthus Therapeutics\njdavisruff@dianthustx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c9002285-2240-4dab-aced-77296f86a3fa)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-01T20:30:01.967448003Z","server_sent_at_ms":1777667401967},"received_at":"2026-05-01T20:30:02.018Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}